Orexo changes the organizational structure and management team to increase focus on development of new products

Core Insights - Orexo AB has announced changes to its organizational structure and management team to enhance focus on the development of new products following the divestment of Zubsolv® in the US market [1] Group 1: Organizational Changes - Lisa Moore has been appointed as Senior Vice President, Products and Portfolio Strategy, responsible for driving the long-term product vision and ensuring the portfolio meets customer needs [1] - Robert DeLuca, President of Orexo US Inc., will retire but will continue to support the company in an advisory role after May 2026 [1] - Nikolaj Sorensen, CEO & President of Orexo, emphasized the importance of aligning the organization to support long-term priorities and value creation ambitions [1] Group 2: Strategic Focus - The changes aim to sharpen focus on advancing Orexo's pipeline and unlocking the potential of AmorphOX® technology [1] - The company is committed to maintaining commercial and US market competence to address unmet customer needs [1] - Orexo is advancing a diversified pipeline of programs in clinical and preclinical development, leveraging its proprietary AmorphOX® drug delivery technology [1]